Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04532853
Registration number
NCT04532853
Ethics application status
Date submitted
21/08/2020
Date registered
31/08/2020
Date last updated
27/07/2021
Titles & IDs
Public title
Optimizing Maintenance Therapy in COPD Patients
Query!
Scientific title
Optimizing Maintenance Therapy in COPD Patients: Real-world Observational Study of Peak Inspiratory Flow Rate, Inhalation Technique, and Medication Adherence
Query!
Secondary ID [1]
0
0
GPRI20103
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PIFOTAL
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
COPD
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
COPD patients -
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Clinical COPD Questionnaire
Query!
Assessment method [1]
0
0
Self reported health status of COPD
Query!
Timepoint [1]
0
0
past 7 days (counted from day of study visit)
Query!
Primary outcome [2]
0
0
COPD Assessment Test (CAT)
Query!
Assessment method [2]
0
0
Self reported health status of COPD
Query!
Timepoint [2]
0
0
past 7 days (counted from day of study visit) [Note that the CAT has no explicit time frame]
Query!
Secondary outcome [1]
0
0
COPD Exacerbations
Query!
Assessment method [1]
0
0
Self reported
Query!
Timepoint [1]
0
0
past 12 months (counted from day of study visit)
Query!
Secondary outcome [2]
0
0
Healthcare resource utilization
Query!
Assessment method [2]
0
0
Of primary care (consultations with GPs and primary care nurse), of secondary care (consultations with registrars or medical specialists in outpatient clinics, emergency departments, rate and duration of hospitalizations, and chest imaging/x-rays), of other healthcare provision (lung function technicians, physiotherapists, dietitians, and psychologists), as well as laboratory assessments and medication use.
Query!
Timepoint [2]
0
0
past 6 months (counted from day of study visit)
Query!
Eligibility
Key inclusion criteria
- A clinical diagnosis of COPD;
- Age = 40;
- Use of maintenance therapy through a DPI in the last 3 months or longer
- Sufficient investigator-assessed decision-making capacity to provide informed consent
(patients will not be invited if they have acute psychotic disorders, severe pervasive
developmental disorders / severe intellectual disability or advanced neurodegenerative
disease)
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- An exacerbation in the past 6 weeks (as this requires a patient to recover)
- Life threatening disease and life expectancy < 6 months (as inclusion of these
patients is unethical)
- Participation in a randomized clinical trial on COPD medication
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Retrospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/10/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/07/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1434
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Woolcock Institute of Medical Research, University of Sydney - Sydney
Query!
Recruitment postcode(s) [1]
0
0
- Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
Greece
Query!
State/province [1]
0
0
Heraklion
Query!
Country [2]
0
0
Netherlands
Query!
State/province [2]
0
0
Groningen
Query!
Country [3]
0
0
Poland
Query!
State/province [3]
0
0
Katowice
Query!
Country [4]
0
0
Portugal
Query!
State/province [4]
0
0
Aveiro
Query!
Country [5]
0
0
Spain
Query!
State/province [5]
0
0
Islas Baleares
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
General Practitioners Research Institute
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Boehringer Ingelheim
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Background: Effectiveness of maintenance therapy for COPD with Dry Powder Inhalers (DPIs)
requires an optimal Peak Inspiratory Flow Rate (PIFR), a proper inhalation technique and
adequate medication adherence from patients. Recent studies have suggested that patients with
reduced peak inspiratory flow may have worse COPD-related symptom burden and increased risk
of COPD-related hospitalizations. However, in primary care, little is known about how many
COPD patients have suboptimal PIFR. Furthermore, there is a paucity of knowledge concerning
the associations of PIFR, inhalation technique and medication adherence with the
effectiveness of maintenance therapy.
Objective: To examine associations of PIFR, inhalation technique, and medication adherence
with health status and disease, exacerbations, and healthcare resource utilization in
patients with COPD receiving maintenance treatment with dry powder inhalers.
Study design: Cross-sectional observational study in five European countries*.
Study population: COPD patients aged 40 years or older who have received COPD maintenance
therapy through DPIs in the past 3 months or longer.
Main study parameters: Health status as measured with the Clinical COPD Questionnaire (CCQ),
COPD Assessment Test (CAT), number of exacerbations, an assessment of PIFR, inhalation
technique errors, medication adherence, healthcare resource utilization (HCRU), medication
use and demographic and clinical covariates.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness: No significant burden from participating is expected. Risk of participating is
deemed negligible. In addition, patients may benefit from participating. Specifically,
patients who manifest inhalation errors, will receive a tailored inhalation instruction to
remediate their inhalation errors. The impact of this instruction will not be evaluated in
any way, therefore it should not be seen as an intervention.
* If the preplanned number of patients cannot be included also because of national outbreaks
of SARS-COV-2 resulting in travel restrictions, participation will be sought from researchers
from three other European countries
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04532853
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janwillem Kocks, MD, PhD
Query!
Address
0
0
General Practitioners Research Institute
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04532853
Download to PDF